140 related articles for article (PubMed ID: 6605800)
21. [Prognostic value of the assessment of nonspecific immunologic reactivity in lung cancer].
Porwit-Ksiazek A
Nowotwory; 1982; 32(1-2):71-80. PubMed ID: 6294626
[No Abstract] [Full Text] [Related]
22. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
[TBL] [Abstract][Full Text] [Related]
23. Generation of cytotoxic factor by human large granular lymphocytes during interaction with autologous tumor cells: lysis of fresh human tumor cells.
Uchida A; Klein E
J Natl Cancer Inst; 1988 Nov; 80(17):1398-403. PubMed ID: 3262773
[TBL] [Abstract][Full Text] [Related]
24. [Immune status of patients with bronchial cancer].
Aulenbacher P; Manke HG; Drings P
Klin Wochenschr; 1987 May; 65(10):445-52. PubMed ID: 3037180
[TBL] [Abstract][Full Text] [Related]
25. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer.
Yoshino I; Takenoyama M; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Ogami A; Yano K; Osaki T; Nakanishi R; Ichiyoshi Y; Nomoto K; Yasumoto K
Jpn J Cancer Res; 1997 Aug; 88(8):743-9. PubMed ID: 9330606
[TBL] [Abstract][Full Text] [Related]
26. Induction of killer cells from lymphocytes in pleural effusion of advanced lung cancer patients.
Inoue Y; Shijubo N; Uede T
Jpn J Cancer Res; 1990 Oct; 81(10):1012-20. PubMed ID: 2172193
[TBL] [Abstract][Full Text] [Related]
27. Human tumor-lymphocyte interaction in vitro. III. T lymphocytes in autologous tumor stimulation (ATS).
Vánky F; Klein E; Stjernswärd J; Rodriguez L; Péterffy A; Steiner L; Nilsonne U
Int J Cancer; 1978 Dec; 22(6):679-86. PubMed ID: 309867
[TBL] [Abstract][Full Text] [Related]
28. Immunologic parameters as significant prognostic factors in lung cancer.
Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Konaka C; Kato H
Lung Cancer; 2002 Aug; 37(2):161-9. PubMed ID: 12140139
[TBL] [Abstract][Full Text] [Related]
29. [Postoperative sequential testing of cytotoxic activity against the autologous and allogeneic tumor cells in patients with primary lung resected cancer].
Fujisawa T; Fukasawa T; Saitoh Y; Urabe N; Nomoto Y; Yamakawa H; Baba M; Kimura H; Yamaguchi Y
Gan No Rinsho; 1988 Nov; 34(14):1922-6. PubMed ID: 2849685
[TBL] [Abstract][Full Text] [Related]
30. Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small-cell lung cancer.
Meta M; Ponte M; Guastella M; Semino C; Pietra G; Ratto GB; Melioli G
Cancer Immunol Immunother; 1995 Apr; 40(4):235-40. PubMed ID: 7750121
[TBL] [Abstract][Full Text] [Related]
31. Impaired T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma.
Andreev K; Trufa DI; Siegemund R; Rieker R; Hartmann A; Schmidt J; Sirbu H; Finotto S
Br J Cancer; 2015 Sep; 113(6):902-13. PubMed ID: 26348446
[TBL] [Abstract][Full Text] [Related]
32. Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study.
Iwai K; Soejima K; Kudoh S; Umezato Y; Kaneko T; Yoshimori K; Tokuda H; Yamaguchi T; Mizoo A; Setoguchi Y; Kamigaki T; Fujimoto K; Goto S
Cancer Immunol Immunother; 2012 Oct; 61(10):1781-90. PubMed ID: 22422103
[TBL] [Abstract][Full Text] [Related]
33. Human monocyte-induced tumor cell cytotoxicity.
Rinehart JJ; Lange P; Gormus BJ; Kaplan ME
Blood; 1978 Jul; 52(1):211-20. PubMed ID: 656628
[No Abstract] [Full Text] [Related]
34. DR antigens expressed on tumor cells do not contribute to the blastogenetic response of autologous T cells.
Vánky F; Klein E; Willems J
Cancer Immunol Immunother; 1985; 19(3):219-25. PubMed ID: 3873987
[TBL] [Abstract][Full Text] [Related]
35. Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients.
Uchida A; Kariya Y; Okamoto N; Sugie K; Fujimoto T; Yagita M
J Natl Cancer Inst; 1990 Nov; 82(21):1697-701. PubMed ID: 2231757
[TBL] [Abstract][Full Text] [Related]
36. [Active specific immunotherapy in patients with lung cancer following tumor removal].
Mosienko MD; Dorfman MV; Romashko NI
Vopr Onkol; 1987; 33(3):31-6. PubMed ID: 3494337
[TBL] [Abstract][Full Text] [Related]
37. Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer.
Cannon GB; Dean JH; Herberman RB; Perlin E; Reid J; Miller C; Lang NP
Int J Cancer; 1980 Jan; 25(1):9-17. PubMed ID: 6447114
[TBL] [Abstract][Full Text] [Related]
38. Increased circulating activated T-cells in lung cancer.
Tsuyuguchi I; Shiratsuchi H; Fukuoka M
Chest; 1986 May; 89(5):705-8. PubMed ID: 3009097
[TBL] [Abstract][Full Text] [Related]
39. Immunology of tumor infiltrating lymphocytes.
Holmes EC
Ann Surg; 1985 Feb; 201(2):158-63. PubMed ID: 3155935
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J; Kim S; Kim MY; Go H; Jeon YK; Chung DH
Oncotarget; 2017 Feb; 8(8):13762-13769. PubMed ID: 28099920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
